AirSculpt Technologies (AIRS) Competitors

$4.74 +0.08 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$4.60 -0.14 (-3.04%)

As of 07:44 PM Eastern

AIRS vs. PNTG, WGS, CDNA, INNV, and AGL

Should you buy AirSculpt Technologies stock or one of its competitors? MarketBeat compares AirSculpt Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AirSculpt Technologies include The Pennant Group (PNTG), GeneDx (WGS), CareDx (CDNA), InnovAge (INNV), and Agilon Health (AGL). These companies are all part of the "healthcare" industry.

How does AirSculpt Technologies compare to The Pennant Group?

AirSculpt Technologies (NASDAQ:AIRS) and The Pennant Group (NASDAQ:PNTG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

The Pennant Group has a net margin of 2.96% compared to AirSculpt Technologies' net margin of -7.39%. The Pennant Group's return on equity of 10.07% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.39%	-4.98%	-2.36%
The Pennant Group	2.96%	10.07%	4.23%

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 85.9% of The Pennant Group shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by company insiders. Comparatively, 6.9% of The Pennant Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AirSculpt Technologies presently has a consensus price target of $4.50, indicating a potential downside of 5.06%. The Pennant Group has a consensus price target of $39.00, indicating a potential upside of 5.69%. Given The Pennant Group's stronger consensus rating and higher possible upside, analysts clearly believe The Pennant Group is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
The Pennant Group	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, The Pennant Group had 4 more articles in the media than AirSculpt Technologies. MarketBeat recorded 15 mentions for The Pennant Group and 11 mentions for AirSculpt Technologies. The Pennant Group's average media sentiment score of 0.83 beat AirSculpt Technologies' score of 0.31 indicating that The Pennant Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
The Pennant Group	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AirSculpt Technologies has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, The Pennant Group has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

The Pennant Group has higher revenue and earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A
The Pennant Group	$947.71M	1.35	$29.58M	$0.85	43.41

Summary

The Pennant Group beats AirSculpt Technologies on 12 of the 16 factors compared between the two stocks.

How does AirSculpt Technologies compare to GeneDx?

AirSculpt Technologies (NASDAQ:AIRS) and GeneDx (NASDAQ:WGS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

AirSculpt Technologies has higher earnings, but lower revenue than GeneDx. AirSculpt Technologies is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A

AirSculpt Technologies presently has a consensus price target of $4.50, indicating a potential downside of 5.06%. GeneDx has a consensus price target of $96.43, indicating a potential upside of 148.21%. Given GeneDx's stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

AirSculpt Technologies has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, GeneDx has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market.

91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 44.6% of AirSculpt Technologies shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AirSculpt Technologies has a net margin of -7.39% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.39%	-4.98%	-2.36%
GeneDx	-17.58%	9.15%	5.21%

In the previous week, GeneDx had 11 more articles in the media than AirSculpt Technologies. MarketBeat recorded 22 mentions for GeneDx and 11 mentions for AirSculpt Technologies. GeneDx's average media sentiment score of 0.52 beat AirSculpt Technologies' score of 0.31 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GeneDx	2 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GeneDx beats AirSculpt Technologies on 11 of the 16 factors compared between the two stocks.

How does AirSculpt Technologies compare to CareDx?

CareDx (NASDAQ:CDNA) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

AirSculpt Technologies has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than AirSculpt Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	2.79	-$21.35M	-$0.16	N/A
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A

CareDx presently has a consensus target price of $25.00, indicating a potential upside of 22.01%. AirSculpt Technologies has a consensus target price of $4.50, indicating a potential downside of 5.06%. Given CareDx's stronger consensus rating and higher possible upside, equities analysts plainly believe CareDx is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

CareDx has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

91.5% of AirSculpt Technologies shares are owned by institutional investors. 4.4% of CareDx shares are owned by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CareDx has a net margin of -2.01% compared to AirSculpt Technologies' net margin of -7.39%. CareDx's return on equity of -2.65% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	-2.01%	-2.65%	-1.96%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

In the previous week, AirSculpt Technologies had 9 more articles in the media than CareDx. MarketBeat recorded 11 mentions for AirSculpt Technologies and 2 mentions for CareDx. CareDx's average media sentiment score of 1.31 beat AirSculpt Technologies' score of 0.31 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AirSculpt Technologies	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

CareDx beats AirSculpt Technologies on 11 of the 16 factors compared between the two stocks.

How does AirSculpt Technologies compare to InnovAge?

InnovAge (NASDAQ:INNV) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

AirSculpt Technologies has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than AirSculpt Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.18	-$30.31M	-$0.09	N/A
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A

InnovAge has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

InnovAge presently has a consensus target price of $7.00, suggesting a potential downside of 5.79%. AirSculpt Technologies has a consensus target price of $4.50, suggesting a potential downside of 5.06%. Given AirSculpt Technologies' higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

12.3% of InnovAge shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 1.0% of InnovAge shares are owned by company insiders. Comparatively, 44.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InnovAge has a net margin of -1.22% compared to AirSculpt Technologies' net margin of -7.39%. InnovAge's return on equity of -4.73% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

In the previous week, AirSculpt Technologies had 5 more articles in the media than InnovAge. MarketBeat recorded 11 mentions for AirSculpt Technologies and 6 mentions for InnovAge. AirSculpt Technologies' average media sentiment score of 0.31 beat InnovAge's score of 0.28 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AirSculpt Technologies	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

AirSculpt Technologies beats InnovAge on 9 of the 15 factors compared between the two stocks.

How does AirSculpt Technologies compare to Agilon Health?

Agilon Health (NYSE:AGL) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

AirSculpt Technologies has lower revenue, but higher earnings than Agilon Health. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.82B	0.22	-$391.35M	-$21.56	N/A
AirSculpt Technologies	$151.82M	2.20	-$11.67M	-$0.17	N/A

Agilon Health has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

91.5% of AirSculpt Technologies shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by company insiders. Comparatively, 44.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, AirSculpt Technologies had 1 more articles in the media than Agilon Health. MarketBeat recorded 11 mentions for AirSculpt Technologies and 10 mentions for Agilon Health. Agilon Health's average media sentiment score of 0.68 beat AirSculpt Technologies' score of 0.31 indicating that Agilon Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilon Health	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AirSculpt Technologies	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Agilon Health presently has a consensus target price of $39.48, suggesting a potential downside of 49.46%. AirSculpt Technologies has a consensus target price of $4.50, suggesting a potential downside of 5.06%. Given AirSculpt Technologies' higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Agilon Health has a net margin of -6.09% compared to AirSculpt Technologies' net margin of -7.39%. AirSculpt Technologies' return on equity of -4.98% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-6.09%	-146.03%	-24.55%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

Summary

AirSculpt Technologies beats Agilon Health on 9 of the 16 factors compared between the two stocks.

Get AirSculpt Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIRS vs. The Competition

Export

Metric	AirSculpt Technologies	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$328.74M	$3.77B	$6.29B	$12.38B
Dividend Yield	N/A	2.12%	3.18%	5.35%
P/E Ratio	-27.88	55.23	31.59	25.61
Price / Sales	2.20	54.58	434.26	78.77
Price / Cash	261.18	39.69	23.10	56.33
Price / Book	3.34	5.55	6.83	6.96
Net Income	-$11.67M	$32.12M	$200.71M	$333.52M
7 Day Performance	36.99%	1.28%	-0.58%	0.45%
1 Month Performance	80.92%	3.75%	1.38%	4.06%
1 Year Performance	39.82%	34.96%	36.39%	36.24%

AirSculpt Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIRS AirSculpt Technologies	1.6889 of 5 stars	$4.74 +1.7%	$4.50 -5.1%	+32.4%	$328.74M	$151.82M	N/A	240	Earnings Report Analyst Forecast Options Volume
PNTG The Pennant Group	3.1367 of 5 stars	$35.42 +3.8%	$39.00 +10.1%	+22.0%	$1.19B	$947.71M	41.67	9,700
WGS GeneDx	3.7897 of 5 stars	$39.49 -0.3%	$96.43 +144.2%	-36.1%	$1.18B	$427.54M	N/A	1,300	Insider Trade
CDNA CareDx	2.8463 of 5 stars	$21.40 -0.7%	$25.00 +16.8%	+27.8%	$1.11B	$379.80M	N/A	740	Positive News
INNV InnovAge	1.3687 of 5 stars	$7.55 +2.6%	$7.00 -7.3%	+86.6%	$999.02M	$853.70M	N/A	2,440

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIRS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AirSculpt Technologies (AIRS) Competitors

AIRS vs. PNTG, WGS, CDNA, INNV, and AGL

How does AirSculpt Technologies compare to The Pennant Group?

Summary

How does AirSculpt Technologies compare to GeneDx?

Summary

How does AirSculpt Technologies compare to CareDx?

Summary

How does AirSculpt Technologies compare to InnovAge?

Summary

How does AirSculpt Technologies compare to Agilon Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIRS vs. The Competition

AirSculpt Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AirSculpt Technologies (AIRS) Competitors

AIRS vs. PNTG, WGS, CDNA, INNV, and AGL

How does AirSculpt Technologies compare to The Pennant Group?

Is AIRS or PNTG more profitable?

Do institutionals & insiders believe in AIRS or PNTG?

Do analysts recommend AIRS or PNTG?

Does the media refer more to AIRS or PNTG?

Which has more risk and volatility, AIRS or PNTG?

Which has preferable valuation and earnings, AIRS or PNTG?

Summary

How does AirSculpt Technologies compare to GeneDx?

Which has better valuation & earnings, AIRS or WGS?

Do analysts recommend AIRS or WGS?

Which has more volatility & risk, AIRS or WGS?

Do insiders and institutionals believe in AIRS or WGS?

Is AIRS or WGS more profitable?

Does the media refer more to AIRS or WGS?

Summary

How does AirSculpt Technologies compare to CareDx?

Which has higher earnings and valuation, CDNA or AIRS?

Do analysts prefer CDNA or AIRS?

Which has more volatility and risk, CDNA or AIRS?

Do insiders & institutionals have more ownership in CDNA or AIRS?

Is CDNA or AIRS more profitable?

Does the media prefer CDNA or AIRS?

Summary

How does AirSculpt Technologies compare to InnovAge?

Which has stronger earnings & valuation, INNV or AIRS?

Which has more volatility & risk, INNV or AIRS?

Do analysts prefer INNV or AIRS?

Do institutionals & insiders have more ownership in INNV or AIRS?

Is INNV or AIRS more profitable?

Does the media favor INNV or AIRS?

Summary

How does AirSculpt Technologies compare to Agilon Health?

Which has stronger earnings & valuation, AGL or AIRS?

Which has more volatility & risk, AGL or AIRS?

Do institutionals & insiders have more ownership in AGL or AIRS?

Does the media favor AGL or AIRS?

Do analysts prefer AGL or AIRS?

Is AGL or AIRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIRS vs. The Competition

AirSculpt Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools